Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Silverback Therapeutics, Inc. (SBTX)

5.87   0.06 (1.03%) 11-09 00:00
Open: 5.82 Pre. Close: 5.81
High: 6.15 Low: 5.82
Volume: 116,690 Market Cap: 550(M)

Technical analysis

as of: 2022-11-18 4:24:33 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 7.58     One year: 8.85
Support: Support1: 5.59    Support2: 5.03
Resistance: Resistance1: 6.48    Resistance2: 7.58
Pivot: 5.97
Moving Average: MA(5): 5.86     MA(20): 5.95
MA(100): 5.17     MA(250): 4.7
MACD: MACD(12,26): 0     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 32.2     %D(3): 33.9
RSI: RSI(14): 53.5
52-week: High: 7.54  Low: 2.79
Average Vol(K): 3-Month: 166 (K)  10-Days: 122 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SBTX ] has closed above bottom band by 32.2%. Bollinger Bands are 37.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.16 - 6.19 6.19 - 6.22
Low: 5.74 - 5.78 5.78 - 5.81
Close: 5.81 - 5.87 5.87 - 5.92

Company Description

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Headline News

Sun, 20 Nov 2022
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake ... - Nasdaq

Fri, 21 Oct 2022
Silverback Therapeutics, Inc. announces the FDA's acceptance of ... - Business Wire

Mon, 25 Jul 2022
Silverback Therapeutics plans merger with San Diego biotech - The Business Journals

Thu, 21 Jul 2022
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger - Business Wire

Fri, 08 Apr 2022
Silverback Therapeutics Inc. - Investing News Network

Thu, 31 Mar 2022
Silverback Therapeutics Updates Strategic Priorities and Reports ... - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 35 (M)
Shares Float 22 (M)
% Held by Insiders 1.6 (%)
% Held by Institutions 80.1 (%)
Shares Short 898 (K)
Shares Short P.Month 543 (K)

Stock Financials

EPS -2.74
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.92
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -17.2
Return on Equity (ttm) -28.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.54
Qtrly Earnings Growth 0
Operating Cash Flow -75 (M)
Levered Free Cash Flow -43 (M)

Stock Valuations

PE Ratio -2.16
PEG Ratio 0
Price to Book value 0.74
Price to Sales 0
Price to Cash Flow -2.77

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.